NEWS
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
FOR IMMEDIATE RELEASE WEST CHESTER, Pa. (BUSINESS WIRE) — Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of…
Read more MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
MTTI Reports on Fast-Acting Sprayable Molecule to Visualize Tumors for Real-Time Fluorescence-Guided Cytoreductive Surgery
FOR IMMEDIATE RELEASE West Chester, PA, September 12, 2024, 6:01 am Eastern Standard Time (Business Wire) –Molecular Targeting Technologies,…
MTTI at the 2nd Annual Targeted Radionuclide Pharmaceuticals Supply Chain & Manufacturing Summit
FOR IMMEDIATE RELEASE September 11, 2024, 6:01 am Eastern Standard Time, West Chester, PA (Business Wire) Molecular Targeting Technologies,…
MTTI Reports on 225Ac-EBTATE and 177Lu-EBTATE Radiopharmaceuticals at 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
FOR IMMEDIATE RELEASE West Chester, PA, May 21, 2024, 6:01 am Eastern Standard Time (Business Wire)–Molecular Targeting Technologies, Inc.…
Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore receiveHSA approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
FOR IMMEDIATE RELEASE West Chester, PA, and Singapore, August 2, 2023 — Molecular Targeting Technologies, Inc. (MTTI), and its…
MTTI Highlights Promising One-Year Follow-Up on Ebtate Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion
FOR IMMEDIATE RELEASE West Chester, PA June 21, 2023 — Molecular Targeting Technologies, Inc. (MTTI) announced promising results from…
ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Molecular
Ready to learn more?
Reach out to us to learn more about EvaThera, MTTI, and the future of radiopharmaceuticals
